<DOC>
	<DOCNO>NCT01437722</DOCNO>
	<brief_summary>The purpose clinical study determine efficacy SPL7013 Gel prevention recurrence bacterial vaginosis .</brief_summary>
	<brief_title>Dose-ranging Study SPL7013 Gel Prevention Bacterial Vaginosis ( BV )</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Women age 1845 year history recurrent BV , define least 3 documented episode previous 12 month ( include current episode ) . Current episode BV define subjectreported symptom Amsel 's Criteria Otherwise healthy No active STIs and/or current UTI Previous exposure SPL7013 Gel A Papanicolaou ( Pap ) smear result consider clinically significant ( ie , high grade cervical intraepithelial squamous lesion [ HSIL ] cytology cervical intraepithelial neoplasia [ CIN ] grade CIN2 CIN3 histology ) previous 2 year accordance local treatment guideline .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>BV</keyword>
	<keyword>Bacterial vaginosis</keyword>
	<keyword>recurrent</keyword>
	<keyword>SPL7013 Gel</keyword>
	<keyword>VivaGel</keyword>
</DOC>